uracil has been researched along with Hyperglycemia in 15 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alogliptin improves steroid-induced hyperglycemia by decrease of glucagon levels through an increase in plasma GLP-1 levels." | 7.80 | Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels. ( Fujigaki, Y; Fujikura, T; Isobe, S; Iwakura, T; Kato, A; Naito, Y; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H, 2014) |
| "The EXAMINE trial randomized 5380 patients with type 2 diabetes (T2DM) and a recent acute coronary syndrome (ACS) event, in 49 countries, to double-blind treatment with alogliptin or placebo in addition to standard of care." | 5.24 | Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Gourlie, NM; Heller, SR; Kupfer, S; Liu, Y; Mehta, CR; Nissen, SE; White, WB; Wilson, CA; Zannad, F, 2017) |
| "Alogliptin monotherapy maintained glycaemic control comparable to that of glipizide in elderly patients with T2DM over 1 year of treatment, with substantially lower risk of hypoglycaemia and without weight gain." | 5.17 | Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. ( Fleck, P; Rosenstock, J; Wilson, C, 2013) |
| " The moderate hyperglycaemia seen in prediabetes can be treated using a combination of metformin and lifestyle interventions (low-calorie diets and exercising)." | 4.12 | Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats. ( Akinnuga, AM; Booysen, IN; Ismail, MB; Khathi, A; Khumalo, B; Ngubane, P; Sibiya, NH; Siboto, A, 2022) |
| "Alogliptin improves steroid-induced hyperglycemia by decrease of glucagon levels through an increase in plasma GLP-1 levels." | 3.80 | Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels. ( Fujigaki, Y; Fujikura, T; Isobe, S; Iwakura, T; Kato, A; Naito, Y; Ohashi, N; Ono, M; Sakao, Y; Tsuji, N; Tsuji, T; Yasuda, H, 2014) |
| " The overall incidence rates of treatment-emergent adverse events were similar among the treatment groups." | 2.80 | Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study. ( Igeta, M; Kaku, K; Katou, M; Ohira, T; Sano, H, 2015) |
| "Accordingly, we diagnosed fulminant type 1 diabetes." | 2.52 | The development of fulminant type 1 diabetes during chemotherapy for rectal cancer. ( Adachi, J; Gotyo, N; Mimura, M; Watanabe, T, 2015) |
| "Alogliptin is a DPP-4 inhibitor that can help in improving glycemic control in patients with type 2 diabetes, including the elderly." | 2.50 | Alogliptin benzoate for the treatment of type 2 diabetes. ( Seino, Y; Yabe, D, 2014) |
| "Treatment of patients with type 2 diabetes mellitus (T2DM) traditionally has involved a progression of phases, from conventional lifestyle interventions and monotherapy, to combination therapy involving oral agents, to insulin initiation and its use either alone or with oral pharmacotherapy." | 2.46 | The physiologic role of incretin hormones: clinical applications. ( Cefalu, WT, 2010) |
| "Successful management of type 2 diabetes mellitus (T2DM) requires attention to additional conditions often associated with hyperglycemia including overweight or obesity, dyslipidemia and hypertension, as each has some relationship with microvascular or macrovascular complications." | 2.46 | Managing type 2 diabetes in the primary care setting: beyond glucocentricity. ( Kuritzky, L, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (93.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Siboto, A | 2 |
| Akinnuga, AM | 2 |
| Khumalo, B | 2 |
| Ismail, MB | 2 |
| Booysen, IN | 2 |
| Sibiya, NH | 2 |
| Ngubane, P | 2 |
| Khathi, A | 2 |
| Takayanagi, R | 1 |
| Uchida, T | 1 |
| Kimura, K | 1 |
| Yamada, Y | 1 |
| Rosenstock, J | 1 |
| Wilson, C | 2 |
| Fleck, P | 2 |
| Pratley, RE | 1 |
| Seino, Y | 1 |
| Yabe, D | 1 |
| Ohashi, N | 1 |
| Tsuji, N | 1 |
| Naito, Y | 1 |
| Iwakura, T | 1 |
| Isobe, S | 1 |
| Ono, M | 1 |
| Fujikura, T | 1 |
| Tsuji, T | 1 |
| Sakao, Y | 1 |
| Yasuda, H | 1 |
| Kato, A | 1 |
| Fujigaki, Y | 1 |
| Adachi, J | 1 |
| Mimura, M | 1 |
| Gotyo, N | 1 |
| Watanabe, T | 1 |
| Kaku, K | 1 |
| Katou, M | 1 |
| Igeta, M | 1 |
| Ohira, T | 1 |
| Sano, H | 1 |
| Heller, SR | 1 |
| Bergenstal, RM | 1 |
| White, WB | 1 |
| Kupfer, S | 1 |
| Bakris, GL | 1 |
| Cushman, WC | 1 |
| Mehta, CR | 1 |
| Nissen, SE | 1 |
| Wilson, CA | 1 |
| Zannad, F | 1 |
| Liu, Y | 1 |
| Gourlie, NM | 1 |
| Cannon, CP | 1 |
| Ji, L | 1 |
| Li, L | 1 |
| Kuang, J | 1 |
| Yang, T | 1 |
| Kim, DJ | 1 |
| Kadir, AA | 1 |
| Huang, CN | 1 |
| Lee, D | 1 |
| Cefalu, WT | 1 |
| Kuritzky, L | 1 |
| Gerich, J | 1 |
| Kutoh, E | 1 |
| Ukai, Y | 1 |
| Kusunoki, Y | 1 |
| Katsuno, T | 1 |
| Myojin, M | 1 |
| Miyakoshi, K | 1 |
| Ikawa, T | 1 |
| Matsuo, T | 1 |
| Ochi, F | 1 |
| Tokuda, M | 1 |
| Murai, K | 1 |
| Miuchi, M | 1 |
| Hamaguchi, T | 1 |
| Miyagawa, J | 1 |
| Namba, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes[NCT01023581] | Phase 3 | 784 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). (NCT01023581)
Timeframe: Baseline and Week 26.
| Intervention | percentage glycosylated hemoglobin (Least Squares Mean) |
|---|---|
| Placebo | 0.15 |
| Alogliptin 25 QD | -0.52 |
| Alogliptin 12.5 BID | -0.56 |
| Metformin 500 BID | -0.65 |
| Metformin 1000 BID | -1.11 |
| Alogliptin 12.5 BID + Metformin 500 BID | -1.22 |
| Alogliptin 12.5 BID + Metformin 1000 BID | -1.55 |
The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate. (NCT01023581)
Timeframe: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
| Intervention | mg/dL (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 1 (n=102, 103, 94, 95, 104, 101, 109) | Week 2 (n=105, 112, 105, 102, 108, 106, 111) | Week 4 (n=105, 112, 106, 106, 110, 106, 111) | Week 8 (n=105, 112, 106, 106, 110, 106, 112) | Week 12 (n=105, 112, 106, 106, 110, 106, 112) | Week 16 (n=105, 112, 106, 106, 110, 106, 112) | Week 20 (n=105, 112, 106, 106, 110, 106, 112) | Week 26 (n=105, 112, 106, 106, 110, 106, 112) | |
| Alogliptin 12.5 BID | -11.9 | -11.6 | -16.6 | -12.1 | -14.7 | -14.7 | -12.3 | -9.7 |
| Alogliptin 12.5 BID + Metformin 1000 BID | -36.3 | -43.6 | -44.1 | -43.8 | -44.7 | -47.7 | -44.6 | -45.9 |
| Alogliptin 12.5 BID + Metformin 500 BID | -32.7 | -34.5 | -37.6 | -32.9 | -31.6 | -35.9 | -33.8 | -31.7 |
| Alogliptin 25 QD | -3.9 | -7.4 | -11.5 | -10.9 | -9.7 | -7.1 | -9.2 | -6.1 |
| Metformin 1000 BID | -23.1 | -22.2 | -29.0 | -30.7 | -30.7 | -33.5 | -35.1 | -31.9 |
| Metformin 500 BID | -12.6 | -14.5 | -16.9 | -11.8 | -14.0 | -13.3 | -10.9 | -11.5 |
| Placebo | 5.7 | 4.6 | 7.2 | 7.1 | 11.6 | 10.1 | 8.7 | 12.4 |
"The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20.~Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate." (NCT01023581)
Timeframe: Baseline and Weeks 4, 8, 12, 16, and 20.
| Intervention | percentage glycosylated hemoglobin (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Week 4 (n=95, 97, 89, 94, 102, 94, 101) | Week 8 (n=102, 104, 104, 103, 108, 102, 111) | Week 12 (n=102, 104, 104, 103, 108, 102, 111) | Week 16 (n=102, 104, 104, 103, 108, 102, 111) | Week 20 (n=102, 104, 104, 103, 108, 102, 111) | |
| Alogliptin 12.5 BID | -0.42 | -0.58 | -0.62 | -0.63 | -0.59 |
| Alogliptin 12.5 BID + Metformin 1000 BID | -0.75 | -1.17 | -1.40 | -1.50 | -1.54 |
| Alogliptin 12.5 BID + Metformin 500 BID | -0.70 | -1.08 | -1.22 | -1.26 | -1.25 |
| Alogliptin 25 QD | -0.34 | -0.51 | -0.53 | -0.58 | -0.57 |
| Metformin 1000 BID | -0.58 | -0.86 | -1.02 | -1.09 | -1.14 |
| Metformin 500 BID | -0.37 | -0.59 | -0.68 | -0.72 | -0.68 |
| Placebo | 0.09 | 0.08 | 0.12 | 0.13 | 0.12 |
5 reviews available for uracil and Hyperglycemia
| Article | Year |
|---|---|
Alogliptin benzoate for the treatment of type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combinat | 2014 |
The development of fulminant type 1 diabetes during chemotherapy for rectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Diabetes Mellitus, Type 1; Diabetic Ketoacido | 2015 |
The physiologic role of incretin hormones: clinical applications.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progr | 2010 |
Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl | 2010 |
7 trials available for uracil and Hyperglycemia
3 other studies available for uracil and Hyperglycemia
| Article | Year |
|---|---|
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Ameliorative Effects of a Rhenium (V) Compound with Uracil-Derived Ligand Markers Associated with Hyperglycaemia-Induced Renal Dysfunction in Diet-Induced Prediabetic Rats.
Topics: Animals; Diabetes Mellitus, Type 2; Diet; Glomerular Filtration Rate; Hyperglycemia; Kidney; Kidney | 2022 |
Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response | 2018 |
Alogliptin improves steroid-induced hyperglycemia in treatment-naïve Japanese patients with chronic kidney disease by decrease of plasma glucagon levels.
Topics: Aged; Asian People; Body Mass Index; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; | 2014 |